ARS Pharmaceuticals Faces Class Action After Insurance Coverage Issues: Key Deadlines and Impact on Investors

Investor Alert: Class Action Lawsuit Against ARS Pharmaceuticals

Pomerantz Law Firm has announced an ongoing class action lawsuit targeting ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). Investors who have incurred losses on their investment during the relevant period are urged to participate in the lawsuit. If you have purchased or acquired securities of ARS during this period, you have until October 5, 2026, to request the court to appoint you as the Lead Plaintiff.

The lawsuit stems from claims that ARS Pharmaceuticals, together with selected officers and directors, may have engaged in securities fraud and other unlawful business practices. The legal action highlights the responsibility of corporate leaders to uphold transparency with investors and maintain ethical conduct.

The situation escalated dramatically when, on June 24, 2026, ARS Pharmaceuticals reported they had failed to secure expanded insurance coverage for their epinephrine nasal spray product, known as Neffy. CVK Caremark, their insurance provider, postponed their coverage decision until January 2027, which sent alarm bells among investors. Following this announcement, shares of ARS Pharmaceuticals plummeted by $2.52, equating to a staggering decline of 23.91%, closing at $8.02 per share on June 25, 2026.

For those interested in potentially joining the class action, the firm recommends contacting Danielle Peyton at Pomerantz LLP via email at [email protected] or by calling 646-581-9980 (or toll-free at 888.4-POMLAW), providing necessary personal details including your mailing address and a phone number. The firm encourages timely inquiry about the proceedings to ensure eligibility as class members.

Pomerantz LLP is well-known for its focus on corporate, securities, and antitrust class litigation. Over its 85 years of operation, the firm has gained a reputation for advocating vigorously for investors affected by securities fraud and corporate misconduct. They have successfully recovered numerous multimillion-dollar settlements for their clients.

More details about the class action lawsuit can be found on Pomerantz's website at www.pomerantzlaw.com, where a copy of the Complaint is also available.

As this class action unfolds, investors will want to keep a close eye on developments, especially with the upcoming deadlines signifying crucial opportunities for asserting their claims. The integrity of the involved parties will likely come under scrutiny as the case progresses, making this a significant moment for stakeholders in ARS Pharmaceuticals.

Pomerantz LLP continues to fight for the rights of the affected investors, upholding the principles established by its founder, the late Abraham L. Pomerantz, who is regarded as a pioneer in the class action arena.

It's critical for investors facing similar circumstances to act promptly. The outcomes of this lawsuit could hold substantial implications not just for ARS Pharmaceuticals, but also for the broader market and investor trust in corporate practices moving forward.